YU45078B - Process for obtaining a monoclonal antibody - Google Patents

Process for obtaining a monoclonal antibody

Info

Publication number
YU45078B
YU45078B YU3067/80A YU306780A YU45078B YU 45078 B YU45078 B YU 45078B YU 3067/80 A YU3067/80 A YU 3067/80A YU 306780 A YU306780 A YU 306780A YU 45078 B YU45078 B YU 45078B
Authority
YU
Yugoslavia
Prior art keywords
monoclonal antibody
obtaining
hybrid
caf
immunized
Prior art date
Application number
YU3067/80A
Other languages
English (en)
Other versions
YU306780A (en
Inventor
P C S Kung
G Goldstein
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU45078(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Priority to SI8013067A priority Critical patent/SI8013067A8/sl
Publication of YU306780A publication Critical patent/YU306780A/xx
Publication of YU45078B publication Critical patent/YU45078B/xx
Priority to HRP-3067/80A priority patent/HRP940824B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hybrid Cells (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YU3067/80A 1979-12-04 1980-12-03 Process for obtaining a monoclonal antibody YU45078B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8013067A SI8013067A8 (sl) 1979-12-04 1980-12-03 Postopek za pripravo monoklonalnega protitelesa
HRP-3067/80A HRP940824B1 (en) 1979-12-04 1994-10-26 Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/100,072 US4364935A (en) 1979-12-04 1979-12-04 Monoclonal antibody to a human prothymocyte antigen and methods of preparing same

Publications (2)

Publication Number Publication Date
YU306780A YU306780A (en) 1984-04-30
YU45078B true YU45078B (en) 1992-03-10

Family

ID=22277974

Family Applications (1)

Application Number Title Priority Date Filing Date
YU3067/80A YU45078B (en) 1979-12-04 1980-12-03 Process for obtaining a monoclonal antibody

Country Status (22)

Country Link
US (1) US4364935A (cg-RX-API-DMAC7.html)
EP (1) EP0030815B1 (cg-RX-API-DMAC7.html)
JP (2) JPS5695123A (cg-RX-API-DMAC7.html)
AT (1) ATE13317T1 (cg-RX-API-DMAC7.html)
AU (1) AU545223B2 (cg-RX-API-DMAC7.html)
CA (1) CA1183470A (cg-RX-API-DMAC7.html)
DE (2) DE3070655D1 (cg-RX-API-DMAC7.html)
DK (1) DK153954C (cg-RX-API-DMAC7.html)
ES (1) ES8303097A1 (cg-RX-API-DMAC7.html)
FI (1) FI75365C (cg-RX-API-DMAC7.html)
GR (1) GR72923B (cg-RX-API-DMAC7.html)
HK (1) HK24386A (cg-RX-API-DMAC7.html)
IE (1) IE50725B1 (cg-RX-API-DMAC7.html)
IL (1) IL61624A (cg-RX-API-DMAC7.html)
MY (1) MY8600519A (cg-RX-API-DMAC7.html)
NO (1) NO159888C (cg-RX-API-DMAC7.html)
NZ (1) NZ195647A (cg-RX-API-DMAC7.html)
PH (1) PH17510A (cg-RX-API-DMAC7.html)
PT (1) PT72146B (cg-RX-API-DMAC7.html)
SG (1) SG7386G (cg-RX-API-DMAC7.html)
YU (1) YU45078B (cg-RX-API-DMAC7.html)
ZA (1) ZA807567B (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806349A (en) * 1979-12-04 1989-02-21 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
JPS5823847B2 (ja) * 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
EP0103632B1 (en) * 1982-03-15 1990-12-19 The Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA2310805A1 (en) 1997-11-24 1999-06-03 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
FR2878852B1 (fr) * 2000-09-28 2007-02-23 Imtix Sangstat Procede de production d'immunoglobulines anti-thymocytes humains
US7653260B2 (en) 2004-06-17 2010-01-26 Carl Zeis MicroImaging GmbH System and method of registering field of view
US8582924B2 (en) 2004-06-30 2013-11-12 Carl Zeiss Microimaging Gmbh Data structure of an image storage and retrieval system
TWI423814B (zh) * 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
WO2015123687A1 (en) 2014-02-14 2015-08-20 Centrose, Llc Extracellular targeted drug conjugates
SG11201607983YA (en) 2014-03-28 2016-10-28 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
RS62332B1 (sr) 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MA46534A (fr) 2016-10-14 2019-08-21 Xencor Inc Protéines de fusion fc hétérodimères il15/il15r
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CN114085818A (zh) * 2021-11-19 2022-02-25 蔡开来 一种抗大熊猫Thy1单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
JPS5695123A (en) 1981-08-01
ZA807567B (en) 1982-07-28
GR72923B (cg-RX-API-DMAC7.html) 1984-01-11
DK153954B (da) 1988-09-26
PT72146A (en) 1981-01-01
DK517380A (da) 1981-06-05
IL61624A (en) 1984-07-31
US4364935A (en) 1982-12-21
NO803661L (no) 1981-06-05
EP0030815A3 (en) 1981-12-30
DK153954C (da) 1989-02-20
DE30815T1 (de) 1984-07-19
PH17510A (en) 1984-09-07
NO159888B (no) 1988-11-07
ES8303097A1 (es) 1983-02-16
IE802511L (en) 1981-06-04
YU306780A (en) 1984-04-30
JPS6413988A (en) 1989-01-18
AU6501280A (en) 1981-06-11
MY8600519A (en) 1986-12-31
CA1183470A (en) 1985-03-05
NZ195647A (en) 1984-07-06
HK24386A (en) 1986-04-11
JPS649999B2 (cg-RX-API-DMAC7.html) 1989-02-21
ATE13317T1 (de) 1985-06-15
EP0030815A2 (en) 1981-06-24
AU545223B2 (en) 1985-07-04
ES497425A0 (es) 1982-12-16
PT72146B (en) 1982-07-05
FI75365B (fi) 1988-02-29
FI803757L (fi) 1981-06-05
JPH0159870B2 (cg-RX-API-DMAC7.html) 1989-12-20
NO159888C (no) 1989-02-15
FI75365C (fi) 1988-06-09
SG7386G (en) 1986-11-21
IE50725B1 (en) 1986-06-25
DE3070655D1 (en) 1985-06-20
EP0030815B1 (en) 1985-05-15
IL61624A0 (en) 1981-01-30

Similar Documents

Publication Publication Date Title
YU306780A (en) Process for obtaining a monoclonal antibody
YU44957B (en) Process for obtaining a monoclonal antibody
YU45069B (en) Process of obtaining a monoclonal antibody
YU74280A (en) Process for obtaining a monoclonal antibody
YU306580A (en) Process for obtaining a monoclonal antibody
YU45077B (en) Process for obtaining a monoclonal antibody
IE802508L (en) Monoclonal antibody to thymocytes